Ablynx receives another milestone as Boehringer Ingelheim selects Nanobody candidate for pre-clinical development
03-Feb-2012 -
Ablynx announced that Boehringer Ingelheim has selected, as part of their strategic alliance, a second Nanobody® candidate for pre-clinical development, which triggered a €5 million milestone payment to Ablynx. The Nanobody development candidate is designed to interfere with the function of two ...
Ablynx
Boehringer Ingelheim
milestone payments